These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2858689)

  • 1. New orally active iron chelators.
    Kontoghiorghes GJ
    Lancet; 1985 Apr; 1(8432):817. PubMed ID: 2858689
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
    Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
    Kontoghiorghes GJ
    Arch Toxicol Suppl; 1996; 18():202-14. PubMed ID: 8678796
    [No Abstract]   [Full Text] [Related]  

  • 4. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ
    Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of iron chelators, 1,2-dialkyl-3-hydroxypyridin-4-ones, on the lipid peroxidation and glutathione level in the liver of mice.
    Eybl V; Caisová D; Koutenský J; Kontoghiorghes GJ
    Arch Toxicol Suppl; 1991; 14():185-7. PubMed ID: 1805729
    [No Abstract]   [Full Text] [Related]  

  • 6. Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
    Kontoghiorghes GJ
    Acta Haematol; 1987; 78(2-3):212-6. PubMed ID: 3120474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.
    Kontoghiorghes GJ
    Biochem J; 1986 Jan; 233(1):299-302. PubMed ID: 3954731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis.
    Mitchell KM; Dotson AL; Cool KM; Chakrabarty A; Benedict SH; LeVine SM
    Mult Scler; 2007 Nov; 13(9):1118-26. PubMed ID: 17967839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
    Naves Díaz ML; Elorriaga R; Canteros A; Cannata Andía JB
    Nephrol Dial Transplant; 1998; 13 Suppl 3():23-8. PubMed ID: 9568816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
    Ibrahim AS; Edwards JE; Fu Y; Spellberg B
    J Antimicrob Chemother; 2006 Nov; 58(5):1070-3. PubMed ID: 16928702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
    Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
    J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron mobilisation from transferrin by deferiprone (L1).
    Kontoghiorghes GJ; Kolnagou A; Eracleous E; Evans RW
    Br J Haematol; 2005 Apr; 129(1):157. PubMed ID: 15801969
    [No Abstract]   [Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis.
    Georgiou NA; van der Bruggen T; Oudshoorn M; Hider RC; Marx JJ; van Asbeck BS
    Eur J Clin Invest; 2002 Mar; 32 Suppl 1():91-6. PubMed ID: 11886438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
    Alexiou GA; Gerogianni P; Vartholomatos E; Kyritsis AP
    Cancer Invest; 2016 Nov; 34(10):489-495. PubMed ID: 27768402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.
    Kontoghiorghes GJ; Chambers S; Hoffbrand AV
    Biochem J; 1987 Jan; 241(1):87-92. PubMed ID: 3566714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.
    Liu ZD; Kayyali R; Hider RC; Porter JB; Theobald AE
    J Med Chem; 2002 Jan; 45(3):631-9. PubMed ID: 11806714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.
    Douvas GS; May MH; Kolnagou A; Kontoghiorghes GJ
    Arzneimittelforschung; 2002; 52(1):45-52. PubMed ID: 11838274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute iron intoxication: the efficacy of deferiprone and sodium biocarbonate in the prevention of iron absorption from the digestive tract.
    Barr J; Berkovitch M; Tavori I; Kariv N; Schejter A; Eshel G
    Vet Hum Toxicol; 1999 Oct; 41(5):308-11. PubMed ID: 10509434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxypyridinones and desferrioxamine inhibit macrophage-mediated LDL oxidation by iron but not by copper.
    Lamb DJ; Hider RC; Leake DS
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):234S. PubMed ID: 8224391
    [No Abstract]   [Full Text] [Related]  

  • 20. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.